LEAP study for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study compares a new treatment strategy (called LEAP) to standard care for wet age-related macular degeneration (AMD), a condition where abnormal blood vessels damage the center of your vision. The goal is to see if this approach can safely and effectively improve vision and reduce the need for frequent eye injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older.
- You must have wet age-related macular degeneration (AMD) with active abnormal blood vessels.
- The abnormal blood vessels must be at least a certain distance (about 0.3 mm) from the center of your vision.
- You cannot have very poor vision from bleeding or other eye conditions that would interfere with the study.
- You must not have had a heart attack, stroke, or major heart problem in the last 4 months.
- You must not have uncontrolled high blood pressure or poorly controlled diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.